These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1393 related items for PubMed ID: 17178882

  • 1. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 2. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L, Trail PA, Taylor I, Wilhelm SM.
    Methods Enzymol; 2006 Dec 15; 407():597-612. PubMed ID: 16757355
    [Abstract] [Full Text] [Related]

  • 3. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 15; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 15; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 5. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC.
    J Hepatol; 2010 Jan 15; 52(1):79-87. PubMed ID: 19910069
    [Abstract] [Full Text] [Related]

  • 6. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP, Premkumar DR, Pollack IF.
    J Pharmacol Exp Ther; 2006 Dec 15; 319(3):1070-80. PubMed ID: 16959960
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I, Pollak Y, Broneshter R, Iancu TC.
    FEBS J; 2011 Sep 15; 278(18):3494-507. PubMed ID: 21790999
    [Abstract] [Full Text] [Related]

  • 8. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST.
    Cancer Res; 2005 May 01; 65(9):3691-9. PubMed ID: 15867364
    [Abstract] [Full Text] [Related]

  • 9. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.
    Clin Cancer Res; 2009 Sep 15; 15(18):5820-8. PubMed ID: 19737956
    [Abstract] [Full Text] [Related]

  • 10. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W, Xu B, Li Q, Jiang D, Yan S.
    Mol Med Rep; 2018 Apr 15; 17(4):6185-6193. PubMed ID: 29484394
    [Abstract] [Full Text] [Related]

  • 11. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Apr 15; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 12. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.
    Clin Cancer Res; 2008 Oct 01; 14(19):6146-53. PubMed ID: 18829493
    [Abstract] [Full Text] [Related]

  • 13. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 14. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 15. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM.
    J Pharmacol Exp Ther; 2009 Jun 15; 329(3):1063-70. PubMed ID: 19258520
    [Abstract] [Full Text] [Related]

  • 16. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4.
    Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J, Fabregat I.
    Cancer Res; 2009 Oct 01; 69(19):7595-602. PubMed ID: 19773433
    [Abstract] [Full Text] [Related]

  • 17. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S.
    Circulation; 2008 Nov 11; 118(20):2081-90. PubMed ID: 18955668
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S, Lee SH, Dean NM, McMahon M.
    Cancer Res; 2005 Jun 01; 65(11):4870-80. PubMed ID: 15930308
    [Abstract] [Full Text] [Related]

  • 19. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
    Okano J, Nagahara T, Matsumoto K, Murawaki Y.
    Basic Clin Pharmacol Toxicol; 2008 Jun 01; 102(6):543-51. PubMed ID: 18346049
    [Abstract] [Full Text] [Related]

  • 20. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL.
    J Hepatol; 2010 Jan 01; 52(1):88-95. PubMed ID: 19913321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.